Diagnostic accuracy of <scp>pan‐TRK</scp> immunohistochemistry in differentiating secretory carcinoma from acinic cell carcinoma of salivary gland—A systematic review

Sharma, Pooja; Sivakumar, N.; Pandiar, Deepak

doi:10.1111/jop.13373

Cited by 8 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Strong nuclear expression of pan-TRK is observed in SC cases with NTRK3 rearrangements, accompanied by weak cytoplasmic staining. Immunohistochemical pan-TRK demonstrates high sensitivity (91%) and specificity (close to 100%) in detecting SC of the salivary gland with ETV6-NTRK3 fusion [ 29 , 30 ]. In our patient group, positive results for pan-TRK were found in 4 out of 6 cases.…”

Section: Discussionmentioning

confidence: 99%

Secretory carcinoma of major and minor salivary glands with ETV6-NTRK3 gene fusion: overcoming misdiagnosis in the era of tumour-agnostic therapy with TRK inhibitors

Durzyńska,

Dominiak,

Sosnowska

et al. 2023

View full text Add to dashboard Cite

Introduction Secretory carcinoma (SC) of the salivary gland is an extraordinarily rare tumour. Accurate diagnosis of SC is crucial for understanding the clinical course, prognosis, and selection of optimal therapy. The aim of this research was to analyse retrospectively the clinical and pathological characteristics of patients diagnosed with SC of the salivary gland from 2017 onwards, which aligns with its addition to the World Health Organization classification. Material and methods We conducted a retrospective, single-centre, clinicopathological analysis of patients diagnosed with SC of the salivary gland between 2017 and 2022. The analysis included the evaluation of NTRK3 gene rearrangements and immunohistochemical (IHC) profiling. Results The study included 6 patients, comprising 4 women and 2 men. The average age of the patients was 50 years (standard deviation 26). Three cases presented with tumours in the parotid gland, while one case each involved the submandibular gland, sinonasal tract, and buccal mucosa. Interestingly, despite the characteristic IHC profile, each case was initially diagnosed as a different type of salivary gland cancer. Next-generation sequencing analysis was performed in 3 cases, revealing the presence of the ETV6-NTRK3 fusion gene. This cohort notably features an intriguing case: the youngest patient documented in literature, distinguished by extended follow-up and delayed recurrence. Conclusions In summary, emphasizing the risk of misdiagnosis is pivotal in the context of SC of the salivary gland, which can manifest across diverse glandular sites. Accurate diagnosis, underscored by the assessment of NTRK3 gene rearrangements, assumes a critical role in guiding effective management and treatment decisions.

show abstract

Section: Discussionmentioning

confidence: 99%

Secretory carcinoma of major and minor salivary glands with ETV6-NTRK3 gene fusion: overcoming misdiagnosis in the era of tumour-agnostic therapy with TRK inhibitors

Durzyńska,

Dominiak,

Sosnowska

et al. 2023

View full text Add to dashboard Cite

show abstract

“…MRI can be used in soft tissue lesions, which helps to measure the exact size location of the lesion and if it has invaded locally. Various molecular studies have been made for advances in diagnosing salivary gland pathologies [8][9][10].…”

Section: Discussionmentioning

confidence: 99%

Adenoid Cystic Carcinoma of the Oral Cavity- A Case Report Comparing the Differences and Similarities Between a Child and an Adult Patient

Kasthurirengan¹,

Neralla²,

Pandurangan³

2023

Cureus

View full text Add to dashboard Cite

Adenoid cystic carcinoma is a malignant neoplasm primarily of the salivary gland, which can also involve lacrimal glands and other exocrine glands. Adenoid cystic carcinoma rarely presents in the buccal mucosa and young children, and among the major salivary glands, it rarely occurs in the sublingual gland. We are presenting two cases of Grade 1- adenoid cystic carcinoma. One in the buccal mucosa of an eight-year-old boy and another in the sublingual gland of a 50-year-old female patient. The site and age of occurrence can make a huge difference in diagnosis and treatment planning due to the unpredictability of the lesion. Proper diagnosis, treatment planning, and appropriate treatment help improve the lesion's prognosis. Even though such lesions rarely occur, awareness among the Oral and maxillofacial fraternity is very important in providing proper patient care.

show abstract

“…1C, D). The pan-TRK IHC method is characterized by high sensitivity (91%) and specificity (nearly 100%) for the detection of secretory carcinoma of the salivary gland with ETV6--NTRK3 fusion [33,34]. In some cases, the nuclear reaction may be weakly intense or occur only focally, making the IHC test challenging.…”

Section: Rare Tumors With a Very High Prevalence Of Ntrk Gene Fusionsmentioning

confidence: 99%

Pan-TRK immunohistochemistry as a tool in the screening for NTRK gene fusions in cancer patients

Durzyńska

Michałek

2024

Oncol Clin Pract

View full text Add to dashboard Cite

Therapy with TRK inhibitors is a tumor-agnostic treatment directed against specific molecular changes rather than cancer type. NTRK fusions are rare in most prevalent cancers, accounting for less than 0.5% of cases. However, there is a group of rare cancers in which NTRK fusion is more prevalent. These include secretory carcinoma of the breast and salivary gland, childhood sarcomas, such as infantile fibrosarcoma, and cellular and mixed congenital mesoblastic nephroblastoma. The most common rearrangement pertains to NTRK3 and the most common fusion gene is ETV6. Identifying patients with NTRK gene fusions who would likely benefit from targeted therapy with TRK inhibitors requires practical diagnostic tools and an appropriate management strategy of diagnostic trajectory. The fusions can be detected by molecular biology techniques or pan-TRK immunohistochemistry. The latter detects NTRK1/2/3 gene fusions independently of the resulting fusion gene but does not determine which of them has been rearranged or what the fusion partner is. The sensitivity and specificity of the method reach 97% and 100%, respectively. Other advantages include the relatively low cost, short duration of examination, and broad accessibility of immunohistochemistry laboratories. These characteristics make this method a useful screening tool for detecting patients with NTRK gene fusions.

show abstract

Diagnostic accuracy of pan‐TRK immunohistochemistry in differentiating secretory carcinoma from acinic cell carcinoma of salivary gland—A systematic review

Cited by 8 publications

References 31 publications

Secretory carcinoma of major and minor salivary glands with ETV6-NTRK3 gene fusion: overcoming misdiagnosis in the era of tumour-agnostic therapy with TRK inhibitors

Secretory carcinoma of major and minor salivary glands with ETV6-NTRK3 gene fusion: overcoming misdiagnosis in the era of tumour-agnostic therapy with TRK inhibitors

Adenoid Cystic Carcinoma of the Oral Cavity- A Case Report Comparing the Differences and Similarities Between a Child and an Adult Patient

Pan-TRK immunohistochemistry as a tool in the screening for NTRK gene fusions in cancer patients

Contact Info

Product

Resources

About